VOICED : EEUU autoriza vacuna anticovid de Pfizer/BioNTech para menores de 12 a 15 años

The United States has authorized the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 12 to 15. The vaccine, administered in two doses similar to adults, showed strong antibody responses in trials. Vaccinating adolescents is expected to help curb the pandemic and facilitate full-time school reopenings. From March 2020 to April 2021, about 1.5 million youths aged 11 to 17 contracted COVID-19. Vaccination will be available at pharmacies and later through pediatricians. Pfizer-BioNTech plans to seek emergency use authorization for children aged 2 to 11 by September and for those aged six months to two years by the fourth quarter. Other vaccines, Moderna and Johnson & Johnson, are authorized for adults 18 and older.

What age group has the Pfizer-BioNTech COVID-19 vaccine been authorized for in the United States?

• 16 to 18 years

• 12 to 15 years

• 2 to 5 years

• 6 to 11 years

Why is vaccinating adolescents important in controlling the COVID-19 pandemic?

• They are more likely to develop severe symptoms.

• They do not spread the virus.

• They can spread the virus despite mild symptoms.

• They are the primary source of infection.

How many youths aged 11 to 17 contracted COVID-19 in the U.S. from March 2020 to April 2021?

• 1 million

• 500,000

• 1.5 million

• 2 million

When does Pfizer-BioNTech plan to seek emergency authorization for vaccinating children aged 2 to 11?

• By March

• By December

• By September

• By June

Which vaccines are authorized for adults 18 and older in the United States?

• Pfizer-BioNTech and Moderna

• Moderna and Johnson & Johnson

• Pfizer-BioNTech and AstraZeneca

• Johnson & Johnson and AstraZeneca